Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

This phase I trial studies the side effects and best dose of ruxolitinib (Rux) therapy alone (monotherapy) followed by Rux plus azacitidine (AZA) maintenance therapy and to see how well it works in treating patients with acute myeloid leukemia (AML) who are undergoing reduced intensity allogeneic hematopoietic stem cell transplantation (alloHSCT). AlloHSCT provides the only chance for cure for many patients with AML. AlloHSCT is a procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor. This i

Trial Details

NCT ID
NCT07548983
Phase
PHASE1
Sponsor
OHSU Knight Cancer Institute
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Azacitidine
  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Cyclophosphamide
Locations (sample)
  • Portland, Oregon, United States|45.52345,-122.67621

Key Eligibility Criteria

  • PART A: Willingness to provide written informed consent before any study-specific procedures or interventions are performed. For participants unabl…
  • PART A: Age ≥ 18 years, at the time of consent
  • PART A: All types and categories of AML, as defined by World Health Organization (WHO) 2022, excluding acute promyelocytic leukemia (APL)
  • PART A: In complete remission (CR) or complete remission with incomplete blood count recovery (CRi) after induction of remission for transition to …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →